972 related articles for article (PubMed ID: 17709120)
1. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.
Moreira FA; Kaiser N; Monory K; Lutz B
Neuropharmacology; 2008 Jan; 54(1):141-50. PubMed ID: 17709120
[TBL] [Abstract][Full Text] [Related]
2. Effects of fatty acid amide hydrolase inhibitor URB597 in a rat model of trauma-induced long-term anxiety.
Danandeh A; Vozella V; Lim J; Oveisi F; Ramirez GL; Mears D; Wynn G; Piomelli D
Psychopharmacology (Berl); 2018 Nov; 235(11):3211-3221. PubMed ID: 30251159
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice.
Nozaki C; Markert A; Zimmer A
Eur Neuropsychopharmacol; 2015 Aug; 25(8):1388-96. PubMed ID: 25910421
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.
Walentiny DM; Vann RE; Wiley JL
Neuropharmacology; 2015 Jun; 93():237-42. PubMed ID: 25698527
[TBL] [Abstract][Full Text] [Related]
5. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition.
Scherma M; Medalie J; Fratta W; Vadivel SK; Makriyannis A; Piomelli D; Mikics E; Haller J; Yasar S; Tanda G; Goldberg SR
Neuropharmacology; 2008 Jan; 54(1):129-40. PubMed ID: 17904589
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task.
Varvel SA; Wise LE; Niyuhire F; Cravatt BF; Lichtman AH
Neuropsychopharmacology; 2007 May; 32(5):1032-41. PubMed ID: 17047668
[TBL] [Abstract][Full Text] [Related]
7. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
[TBL] [Abstract][Full Text] [Related]
8. Anti-aversive role of the endocannabinoid system in the periaqueductal gray stimulation model of panic attacks in rats.
Viana TG; Hott SC; Resstel LB; Aguiar DC; Moreira FA
Psychopharmacology (Berl); 2015 May; 232(9):1545-53. PubMed ID: 25388290
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of cue-induced reinstatement of nicotine seeking by URB597 through cannabinoid CB1 receptor in rats.
Forget B; Guranda M; Gamaleddin I; Goldberg SR; Le Foll B
Psychopharmacology (Berl); 2016 May; 233(10):1823-8. PubMed ID: 26864774
[TBL] [Abstract][Full Text] [Related]
10. An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters.
Moise AM; Eisenstein SA; Astarita G; Piomelli D; Hohmann AG
Psychopharmacology (Berl); 2008 Oct; 200(3):333-46. PubMed ID: 18545985
[TBL] [Abstract][Full Text] [Related]
11. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice.
Booker L; Kinsey SG; Abdullah RA; Blankman JL; Long JZ; Ezzili C; Boger DL; Cravatt BF; Lichtman AH
Br J Pharmacol; 2012 Apr; 165(8):2485-96. PubMed ID: 21506952
[TBL] [Abstract][Full Text] [Related]
12. Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.
Celorrio M; Fernández-Suárez D; Rojo-Bustamante E; Echeverry-Alzate V; Ramírez MJ; Hillard CJ; López-Moreno JA; Maldonado R; Oyarzábal J; Franco R; Aymerich MS
Brain Behav Immun; 2016 Oct; 57():94-105. PubMed ID: 27318096
[TBL] [Abstract][Full Text] [Related]
13. A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase.
Carey LM; Slivicki RA; Leishman E; Cornett B; Mackie K; Bradshaw H; Hohmann AG
Mol Pain; 2016; 12():. PubMed ID: 27178246
[TBL] [Abstract][Full Text] [Related]
14. Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat.
Cippitelli A; Cannella N; Braconi S; Duranti A; Tontini A; Bilbao A; Defonseca FR; Piomelli D; Ciccocioppo R
Psychopharmacology (Berl); 2008 Jul; 198(4):449-60. PubMed ID: 18446329
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient mice.
Cassano T; Gaetani S; Macheda T; Laconca L; Romano A; Morgese MG; Cimmino CS; Chiarotti F; Bambico FR; Gobbi G; Cuomo V; Piomelli D
Psychopharmacology (Berl); 2011 Mar; 214(2):465-76. PubMed ID: 21042794
[TBL] [Abstract][Full Text] [Related]
16. Comparison of anandamide transport in FAAH wild-type and knockout neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake.
Ortega-Gutiérrez S; Hawkins EG; Viso A; López-Rodríguez ML; Cravatt BF
Biochemistry; 2004 Jun; 43(25):8184-90. PubMed ID: 15209515
[TBL] [Abstract][Full Text] [Related]
17. CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus.
Béquet F; Uzabiaga F; Desbazeille M; Ludwiczak P; Maftouh M; Picard C; Scatton B; Le Fur G
Eur J Neurosci; 2007 Dec; 26(12):3458-64. PubMed ID: 18052990
[TBL] [Abstract][Full Text] [Related]
18. Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome.
Qin M; Zeidler Z; Moulton K; Krych L; Xia Z; Smith CB
Behav Brain Res; 2015 Sep; 291():164-171. PubMed ID: 25979787
[TBL] [Abstract][Full Text] [Related]
19. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
Kinsey SG; Long JZ; O'Neal ST; Abdullah RA; Poklis JL; Boger DL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2009 Sep; 330(3):902-10. PubMed ID: 19502530
[TBL] [Abstract][Full Text] [Related]
20. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels.
Micale V; Cristino L; Tamburella A; Petrosino S; Leggio GM; Drago F; Di Marzo V
Neuropsychopharmacology; 2009 Feb; 34(3):593-606. PubMed ID: 18580871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
